Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report
RECOVERY Collaborative Group; Peter Horby 1 , Wei Shen Lim 1 , Jonathan R Emberson 1 , Marion Mafham 1 , Jennifer L Bell 1 , Louise Linsell 1 , Natalie Staplin 1 , Christopher Brightling 1 , Andrew Ustianowski 1 , Einas Elmahi 1 , Benjamin Prudon 1 , Christopher Green 1 , Timothy Felton 1 , David Chadwick 1 , Kanchan Rege 1 , Christopher Fegan 1 , Lucy C Chappell 1 , Saul N Faust 1 , Thomas Jaki 1 , Katie Jeffery 1 , Alan Montgomery 1 , Kathryn Rowan 1 , Edmund Juszczak 1 , J Kenneth Baillie 1 , Richard Haynes 1 , Martin J Landray
N Engl J Med. 2020 Jul 17;NEJMoa2021436. doi: 10.1056/NEJMoa2021436. Online ahead of print.
PMID: 32678530 PMCID: PMC7383595 DOI: 10.1056/NEJMoa2021436
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the preliminary results of this comparison.
A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55).
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).